Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.70 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.53 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237091 | 1.00 | FFAR1 (0.70) | FFAR1GABBR2GABBR1HPGDCYP2C19 | |
| SCHEMBL1149768 | 1.00 | FFAR1 (0.70) | FFAR1GABBR2GABBR1HPGDCYP2C19 | |
| Hydrochloric Acid SCHEMBL2005345 | 0.98 | FFAR1 (0.68) | FFAR1GABBR2GABBR1HPGDCYP2C19 | |
| SCHEMBL28324934 | 0.98 | FFAR1 (0.68) | FFAR1GABBR2GABBR1HPGDCYP2C19 | |
| SCHEMBL2899426 | 0.98 | FFAR1 (0.68) | FFAR1GABBR2GABBR1HPGDCYP2C19 | |
| Acetic Acid SCHEMBL159740 | 0.96 | FFAR1 (0.66) | FFAR1GABBR2GABBR1HPGDCYP2C19 | |
| Glycine SCHEMBL8726564 | 0.92 | FFAR1 (0.62) | FFAR1GABBR2GABBR1HPGDCYP2C19 | |
| Azetidine SCHEMBL28247623 | 0.89 | FFAR1 (0.58) | FFAR1GABBR2GABBR1HPGDCYP2C19 | |
| SCHEMBL7858991 | 0.88 | FFAR1 (0.67) | FFAR1 | |
| SCHEMBL21237780 | 0.88 | FFAR1 (0.67) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2377930-B1 | A group of esterases for the enantioselective production of fine and speciality chemicals | BRAIN BIOTECHNOLOGY RES & INFORMATION NETWORK AG (DE) | 2015-12-02 | — | — | EP | claimed |
| EP-1638505-A4 | AMPHIPHILIC PYRIDINIUM COMPOUNDS, METHOD OF MAKING AND USE THEREOF | JACKSON H M FOUND MILITARY MED (US) | 2009-01-07 | — | — | EP | claimed |
| US-20070105916-A1 | Amphiphilic pyridinium compounds, method of making and use thereof | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 2007-05-10 | — | — | US | claimed |
| EP-1638505-A2 | AMPHIPHILIC PYRIDINIUM COMPOUNDS, METHOD OF MAKING AND USE THEREOF | HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005002519-A2 | AMPHIPHILIC PYRIDINIUM COMPOUNDS, METHOD OF MAKING AND USE THEREOF | HENRY M.JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-12168648-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| CN-112867705-B | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3774722-B1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-0409435-B1 | Heteroaryl piperazine antipsychotic agents | PFIZER (US) | 1994-10-26 | — | — | EP | disclosed |
| US-5350747-A | Heteroaryl piperazine antipsychotic agents | PFIZER INC (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1991000863-A1 | HETEROARYL PIPERAZINE ANTIPSYCHOTIC AGENTS | PFIZER INC. (US) | 1991-01-24 | — | — | WO | disclosed |
| EP-0409435-A1 | Heteroaryl piperazine antipsychotic agents | PFIZER INC. (US) | 1991-01-23 | — | — | EP | disclosed |
| US-4438033-A | Steroidal chiral phosphines, methods for their preparation, catalytic systems containing them and catalytic processes in which they are used | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1984-03-20 | — | — | US | disclosed |
| EP-0081149-A1 | New steroidal chiral phosphines, methods for their preparation, catalytic systems containing them and catalytic processes in which they are used | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1983-06-15 | — | — | EP | disclosed |
| US-4198519-A | Anti-inflammatory compounds | BEECHAM GROUP LIMITED (GB) | 1980-04-15 | — | — | US | disclosed |
| US-4153718-A | Anti-inflammatory compounds | BEECHAM GROUP LIMITED (GB) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168648-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | FFAR1 235/4885GABBR2 343/4885GABBR1 397/4885 |
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | FFAR1 543/4885GABBR2 132/4885GABBR1 130/4885 |
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | FFAR1 4027/4885GABBR2 2603/4885GABBR1 3078/4885 |
| US-20070105916-A1 | Amphiphilic pyridinium compounds, method of making and use thereof | CXCL8, IL18, CCR8 | FFAR1 1062/4885GABBR2 3199/4885GABBR1 3603/4885 |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, CTSA | FFAR1 543/4885GABBR2 132/4885GABBR1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.